文献速递前列腺癌

口服达罗他胺单药对比雄激素剥夺治疗激素敏感性前列腺癌男性的2期随机开放标签研究(EORTC-GUCG 1532)

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).
PubMed 文献 · Eur Urol Oncol · 2024-01-24

这项24周开放标签随机2期研究纳入61例需GnRH类似物的激素敏感性前列腺癌男性,分别接受达罗他胺600mg每日两次单药或GnRH类似物治疗。达罗他胺组23例可评估患者中23例(100%)在第24周达到PSA下降>80%的主要终点,中位降幅-99.1%;血清睾酮中位升高44.3,药物相关不良事件发生率48.4%,最常见为男性乳房发育(35.5%)、乏力(12.9%)、潮热(12.9%)和高血压(12.9%)。

要点

  • 达罗他胺单药组23例可评估患者全部(100%)在第24周PSA下降>80%,中位降幅-99.1%。
  • 达罗他胺组48.4%报告药物相关不良事件,多为1或2级;男性乳房发育35.5%。
  • 研究为24周开放标签2期研究,GnRH组结果仅作为内部参照,生活质量的组间比较为描述性。

核心结论

  • 达罗他胺单药在几乎所有激素初治前列腺癌男性中与显著的PSA应答相关。
  • 睾酮水平变化和最常见不良事件(男性乳房发育、乏力、高血压和潮热)与强效雄激素受体抑制一致。

研究设计与样本

  • 这是一项24周、开放标签、随机2期研究,纳入需要促性腺激素释放激素(GnRH)类似物的激素敏感性、组织学确诊前列腺癌患者,美国东部肿瘤协作组体能状态评分为0或1,预期寿命>1年。
  • 所有患者接受达罗他胺600 mg每日两次或市售GnRH类似物;达罗他胺组主要终点为第24周PSA较基线下降≥80%,GnRH组作为内部对照。
  • 共入组61例男性,中位(范围)年龄72岁(53-86岁),42.6%有转移。
  • 达罗他胺组中基线和第24周均有PSA值的可评估人群为23例患者。

主要发现

  • 达罗他胺组23例可评估患者中23例(100%)在第24周达到PSA下降>80%的主要终点,中位(范围)降幅为-99.1%(-91.9%,-100%)。
  • 达罗他胺组第24周血清睾酮较基线中位(范围)升高44.3(5.7-144.0)。
  • 达罗他胺组48.4%的男性报告药物相关不良事件,多为1或2级;最常见的治疗中出现的不良事件包括男性乳房发育(35.5%)、乏力(12.9%)、潮热(12.9%)和高血压(12.9%)。
  • 健康相关生活质量指标为描述性,GnRH组结果将作为内部参考呈现。

临床怎么用

  • 原文结论指出达罗他胺单药在几乎所有激素初治前列腺癌男性中与显著PSA应答相关,睾酮变化和常见不良事件与强效雄激素受体抑制一致。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Darolutamide is an androgen receptor inhibitor that increases overall survival in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive and nonmetastatic castration-resistant prostate cancer (PCa). This phase 2 study assessed the efficacy and safety of darolutamide as monotherapy without ADT in patients with eugonadal testosterone levels. METHODS: This was a 24-wk, open-label, randomized study of patients with hormone-sensitive, histologically confirmed PCa requiring gonadotropin-releasing hormone (GnRH); an Eastern Cooperative Oncology Group performance status score of 0/1; and life expectancy >1 yr. All patients received darolutamide 600 mg bid or a commercially available GnRH analog. The primary endpoint is a prostate-specific antigen (PSA) response, defined as a ≥80% decline at week 24 relative to baseline in the darolutamide study arm. The GnRH arm is used as an internal control. The secondary endpoints included changes in T levels, safety/tolerability, and quality of life. KEY FINDINGS AND LIMITATIONS: Among 61 men enrolled, the median (range) age was 72 yr (53-86 yr); 42.6% of them had metastases. In the darolutamide arm, the evaluable population with available PSA values at baseline and week 24 consisted of 23 patients. Twenty-three (100%) evaluable darolutamide patients achieved a PSA decline of >80% at week 24 (primary endpoint), with a median (range) decrease of -99.1% (-91.9%, -100%). Serum T levels increased by a median (range) of 44.3 (5.7-144.0) at week 24, compared with baseline. In the darolutamide arm, 48.4% of men reported drug-related adverse events (AEs; mostly grade 1 or 2). The most frequent treatment-emergent AEs included gynecomastia (35.5%), fatigue (12.9%), hot flush (12.9%), and hypertension (12.9%). Health-related quality of life measures are descriptive, and GnRH arm results will be presented as an internal reference. CONCLUSIONS AND CLINICAL IMPLICATIONS: Darolutamide monotherapy was associated with a significant PSA response in nearly all men with hormone-naïve PCa. Testosterone-level changes and most common AEs (gynecomastia, fatigue, hypertension, and hot flush) were consistent with potent androgen receptor inhibition. PATIENT SUMMARY: In this study, we report the first use of darolutamide, a novel antiandrogen, as monotherapy without androgen deprivation therapy (ADT). The study shows that darolutamide induce a profound suppression of prostate-specific antigen in all patients, with a safety profile different from that of ADT.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol. 2024. PMID: 38272747. doi:10.1016/j.euo.2024.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。